ET-Kyoto solution

an extracellular-type fluid; contains 4.1% trehalose, hydroxyethyl starch, and gluconate; differs from IT-Kyoto solution in Na and K ionic concentration

Also Known As:

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Aoyama, Akihiro: 1 article (04/2015)
2.	Bando, Toru: 1 article (04/2015)
3.	Chen, Fengshi: 1 article (04/2015)
4.	Date, Hiroshi: 1 article (04/2015)
5.	Ikeda, Masaki: 1 article (04/2015)
6.	Menjyu, Toshi: 1 article (04/2015)
7.	Omasa, Mitsugu: 1 article (04/2015)
8.	Sato, Masaaki: 1 article (04/2015)
9.	Sato, Toshihiko: 1 article (04/2015)
10.	Sonobe, Makoto: 1 article (04/2015)

Related Diseases

1.	Necrosis 03/01/2010 - "The aim of this study was to examine the bile flow and its constituents, markers of graft dysfunction without necrosis in cold ischemic livers, using the following preservation media: UW, ET-Kyoto solution (ET-K) and histidine-tryptophan-ketoglutarate solution (HTK). "
2.	Brain Death (Brain Dead) 01/01/2010 - "Seven islet isolations were performed with the ductal injection of ET-Kyoto solution (DI group) and eight islet isolations were performed without the ductal injection (standard group) using brain-dead donor pancreata. " 04/01/2015 - "From 2002 to 2012, 26 patients underwent transplantation of lungs preserved with ET-Kyoto solution from brain-dead donors. "
3.	Primary Graft Dysfunction 04/01/2015 - "We developed a new lung preservation solution, "ET-Kyoto solution," to enhance lung preservation, to minimize primary graft dysfunction (PGD) and to improve the post-transplant outcomes. "
4.	Weight Gain 09/01/1999 - "The flap weight gain in the IT-K and ET-K solution groups was less than that in EC solution group (p < 0.01). "

Related Drugs and Biologics

1.	Bretschneider cardioplegic solution
2.	Solutions
3.	Prostaglandins D

Related Therapies and Procedures

1.	Transplantation